Beyond Use Dates (BUDs)

Beyond Use Dates (BUDs) are critical dates assigned to compounded medications that indicate when the preparation should no longer be used. Unlike expiration dates provided by manufacturers for commercially available products, BUDs are calculated based on specific criteria and considerations for compounded preparations that are prepared in small quantities for specific patients.

Definition and Importance

A Beyond Use Date is the date after which a compounded preparation should not be used. The determination of an appropriate BUD is essential for maintaining medication safety and efficacy. Unlike manufacturers' expiration dates, which are based on stability testing conducted by the manufacturer following FDA guidelines, BUDs are assigned by compounding pharmacists based on specific considerations related to the compounded preparation.

Why are BUDs important?

They ensure patient safety by indicating when a medication may no longer be stable, potent, or sterile
They help prevent the administration of degraded or contaminated medications
They comply with regulatory requirements for compounded medications
They protect healthcare providers and compounding facilities from liability issues

Factors Affecting Beyond Use Dates

Several factors influence the determination of appropriate Beyond Use Dates:

Formulation Characteristics

Physical state of the preparation (solid, liquid, semi-solid)
pH of the formulation
Presence of preservatives
Water content
Complexity of the formulation

Compounding Process

Aseptic techniques used for sterile preparations
Quality of equipment and facilities
Training and expertise of compounding personnel

Storage Conditions

Temperature requirements
Light sensitivity
Humidity considerations

Container Characteristics

Type of container and closure system
Protective properties against moisture, light, and air
Material compatibility with the preparation

Regulatory Guidelines for BUDs

Various organizations provide guidelines for determining Beyond Use Dates:

United States Pharmacopeia (USP)

USP Chapter <795> provides specific guidance for non-sterile compounding, including recommended BUDs:

Preparation Type	Beyond Use Date
Non-aqueous liquids and solid dosage forms	Not later than the expiration date of the latest ingredient, or 6 months, whichever is earlier
Water-containing solid and solid dosage forms	Not later than 14 days when stored at cold temperatures
Water-containing oral formulations	Not later than 14 days when stored at cold temperatures
All other formulations	Not later than 30 days

USP Chapter <797> addresses sterile compounding and provides guidelines for BUDs based on risk levels:

Risk Level	Beyond Use Date
Low-risk compounded sterile preparations	14 days when stored at controlled room temperature; 45 days when stored refrigerated
Medium-risk compounded sterile preparations	7 days when stored at controlled room temperature; 30 days when stored refrigerated
High-risk compounded sterile preparations	3 days when stored at controlled room temperature

Food and Drug Administration (FDA)

The FDA provides oversight for compounding pharmacies under the Drug Quality and Security Act (DQSA) and other regulations. For 503B outsourcing facilities, the FDA requires compliance with current good manufacturing practice (cGMP) regulations, which include requirements for determining appropriate expiry dates based on stability data.

Determining Beyond Use Dates

The process for determining an appropriate BUD includes:

Information Gathering

Reviewing ingredient information and stability data
Considering the chemical compatibility of all components
Evaluating the intended route of administration
Assessing compounding environment and process

Consideration of Stability Data

When available, direct compatibility and stability data should inform the BUD. This may include:

Published literature on similar compounds
Manufacturer-provided information
Conducting specific stability studies when appropriate

Application of Default Guidelines

In the absence of specific stability data, compounding professionals should apply the default guidelines provided in USP chapters and other regulatory standards.

Note: The appropriate BUD is generally the shorter of: (1) the time determined based on stability data or literature, or (2) the time recommended in applicable regulatory guidelines.

Documentation and Labeling Requirements

Proper documentation and labeling of BUDs are essential for compliance and patient safety:

Documentation

All compounded preparations must have documented BUD determinations
Documentation should include the basis for the assigned BUD
Records must be maintained according to regulatory requirements

Labeling

The BUD must be clearly displayed on the label
Storage conditions must be stated on the label
Labels must comply with state and federal regulations

Best Practices for Managing Beyond Use Dates

Quality Assurance

Implement regular audits of BUD assignments
Establish procedures for verifying BUD calculations
Create systems to track inventory and expiration dates

Storage and Handling

Ensure proper storage conditions as specified on labels
Implement first-expired-first-out inventory management
Train staff on proper handling to maintain preparation integrity

Common Misconceptions About Beyond Use Dates

BUDs and Expiration Dates Are the Same

While both dates indicate when a medication should no longer be used, expiration dates are determined by manufacturers with extensive testing, while BUDs are assigned by compounders based on regulatory guidelines and available information.

Longer BUDs Are Always Better

A longer BUD is not beneficial if it doesn't reflect the actual stability of the preparation. Assigning an excessively long BUD could compromise patient safety.

Visual Inspection Can Replace BUD Monitoring

While visual inspection is important, many degradation processes cannot be detected through observation alone. Strict adherence to BUDs is necessary regardless of appearance.

Conclusion

Beyond Use Dates are essential components of medication safety in compounding practice. They serve as critical indicators of when a compounded preparation should no longer be used, protecting patients from potentially degraded or contaminated medications.

Determining appropriate BUDs requires a comprehensive understanding of the factors affecting stability, regulatory requirements, and best practices in compounding. By following established guidelines, implementing proper documentation and labeling procedures, and continuously updating knowledge in this area, healthcare professionals can ensure patient safety while maximizing the utility of compounded medications.

Reference Files For Beyond Use Dates (BUDs)

Screenshoot